NCT01194856View on ClinicalTrials.gov

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

PHASE4TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
HIV InfectionMitochondrial Dysfunction
Interventions
DRUG

Atazanavir/ritonavir

300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks

DRUG

Efavirenz

Maintain dosage - 600 mg orally QHS for 96 weeks

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Case Western Reserve University

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Cleveland Clinic

OTHER